ARC (NSC 188491) has identical activity to Sangivamycin (NSC 65346) including inhibition of both P-TEFb and PKC

BACKGROUND: The nucleoside analog, ARC (NSC 188491) is a recently characterized transcriptional inhibitor that selectively kills cancer cells and has the ability to perturb angiogenesis in vitro. In this study, the mechanism of action of ARC was further investigated by comparing in vitro and in vivo...

Descripción completa

Detalles Bibliográficos
Autores principales: Stockwin, Luke H, Yu, Sherry X, Stotler, Howard, Hollingshead, Melinda G, Newton, Dianne L
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2651907/
https://www.ncbi.nlm.nih.gov/pubmed/19232100
http://dx.doi.org/10.1186/1471-2407-9-63

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2651907/
https://www.ncbi.nlm.nih.gov/pubmed/19232100
http://dx.doi.org/10.1186/1471-2407-9-63

Ejemplares similares